Literature DB >> 6180046

An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer.

Y Kawade.   

Abstract

Methods of determining and expressing the neutralization titer of anti-interferon antibody were discussed based on considerations of the mass-action law and on experimental data of neutralization of L cell interferon by various antisera. The antibodies in all the sera so far examined were inferred to have low affinities (low association constants compared to the reciprocal of molar concentrations of free interferon), regardless of whether the serum had a low (a few hundred) or high (over 10(5) titer. Then the equilibrium equation can be approximated by a simple formula which relates the antibody concentration to the ratio of total to free interferon concentrations; the absolute amount of interferon neutralized (the difference between total and free interferons) is not involved in computing the titer, and therefore the problem of variations in interferon sensitivity in different assays is eliminated. It is proposed that the neutralization titer be defined, not as the antibody dilution that neutralizes a certain quantity of interferon (such as 10 international units, as often found in the literature), but as the dilution that reduces the interferon titer by a certain factor (taken to be 10 in this paper). A simple formula for calculating the titer from experimental data is given.

Mesh:

Substances:

Year:  1980        PMID: 6180046     DOI: 10.1089/jir.1980.1.61

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  21 in total

1.  Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor.

Authors:  Y Kawade
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

2.  Interferon induction by transfection of Sendai virus C gene cDNA.

Authors:  H Taira; T Kanda; T Omata; H Shibuta; M Kawakita; K Iwasaki
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

3.  Necessity and sufficiency of beta interferon for nitric oxide production in mouse peritoneal macrophages.

Authors:  X Zhang; E W Alley; S W Russell; D C Morrison
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

4.  The preparation of interferon gamma-producing T-cell hybridomas from jacalin-stimulated T lymphocytes and the SH9 T-cell line.

Authors:  I Crane; H Leung; S Barwick; S Parti; A Meager
Journal:  Immunology       Date:  1984-12       Impact factor: 7.397

5.  The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies.

Authors:  Y Kawade; Y Watanabe
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

6.  Constitutive production of human interferons by mouse cells with bovine papillomavirus as a vector.

Authors:  R Fukunaga; Y Sokawa; S Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

Review 7.  Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Authors:  Florian Deisenhammer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Unusual apparently constitutive interferons and antagonists in human placental blood.

Authors:  P Duc-Goiran; B Robert-Galliot; J Lopez; C Chany
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Quantification of the neutralization of cytokine biological activity by antibody: the ten-fold reduction bioassay of interleukin-6 as growth factor.

Authors:  Sidney E Grossberg; Monika Casey; Leslie D Grossberg
Journal:  J Interferon Cytokine Res       Date:  2009-08       Impact factor: 2.607

10.  Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.

Authors:  G Fierlbeck; T Schreiner; G Rassner
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.